Taro Pharmaceuticals Inc

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: $1.6B

Website

Clinical Trials

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Phase 3

Completed

Conditions: Pediculosis

Interventions: Drug: Malathion gel 0.5%
Drug: Permethrin 1% rinse (Nix Crème)

First Posted Date: 2009-08-21

Last Posted Date: 2014-06-13

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 403

Registration Number: NCT00963508

Locations: 🇺🇸
Investigator Site, San Antonio, Texas, United States

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Phase 3

Completed

Conditions: Pediculosis

Interventions: Drug: Permethrin 1% rinse
Drug: Malathion gel 0.5%

First Posted Date: 2009-06-25

Last Posted Date: 2014-08-04

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 254

Registration Number: NCT00927472

Locations: 🇺🇸
Investigator Site, Jonesboro, Arkansas, United States

Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice

Phase 1

Completed

Conditions: Pediculosis

Interventions: Drug: Malathion gel 0.5%
Drug: Malathion lotion 0.5%

First Posted Date: 2009-06-25

Last Posted Date: 2013-12-24

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 24

Registration Number: NCT00927407

Locations: 🇮🇳
Investigator Site, Rabale, Navi Mumbai, India

Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

Phase 1

Completed

Conditions: Tinea Pedis

Interventions: Drug: Butenafine Vehicle manufactured by Taro
Drug: Butenafine cream 1% manufactured by Taro
Drug: Lotrimin Ultra (butenafine) 1%

First Posted Date: 2009-02-03

Last Posted Date: 2014-02-04

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 548

Registration Number: NCT00835510

Locations: 🇧🇿
Investigator Site, Belize City, Belize

Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Tacrolimus 0.1% manufactured by Taro
Drug: Protopic - Tacrolimus 0.1%
Drug: Tacrolimus Vehicle manufactured by Taro

First Posted Date: 2009-01-30

Last Posted Date: 2014-01-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 500

Registration Number: NCT00833079

Bioequivalence Study of Two Imiquimod Cream 5%

Phase 1

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Imiquimod 5% manufactured by Taro
Drug: Aldara - Imiquimod 5%
Drug: Imiquimod Vehicle manufactured by Taro

First Posted Date: 2009-01-26

Last Posted Date: 2014-01-28

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 425

Registration Number: NCT00828568

Locations: 🇺🇸
Investigator Site, Tyler, Texas, United States

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

Phase 2

Completed

Conditions: Pediculosis

Interventions: Drug: MALG (malathion) Treatment

First Posted Date: 2008-09-16

Last Posted Date: 2014-08-07

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 12

Registration Number: NCT00752973

Locations: 🇺🇸
Investigator Site, Jonesboro, Arkansas, United States

T2000 in Essential Tremor - Open Label Continuation

Phase 2

Terminated

Conditions: Essential Tremor

Interventions: Drug: T2000

First Posted Date: 2008-04-09

Last Posted Date: 2013-12-23

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 5

Registration Number: NCT00655278

Locations: 🇨🇦
Investigator Site, Toronto, Ontario, Canada

Pilot Efficacy Study of T2000 in Myoclonus Dystonia

Phase 2

Terminated

Conditions: Myoclonus

Interventions: Drug: T2000

First Posted Date: 2007-07-25

Last Posted Date: 2013-12-23

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 5

Registration Number: NCT00506012

Locations: 🇨🇦
Investigator Site, Toronto, Ontario, Canada

A Study of T2000 in Essential Tremor

Phase 2

Terminated

Conditions: Essential Tremor

Interventions: Drug: T2000

First Posted Date: 2006-05-03

Last Posted Date: 2014-01-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 10

Registration Number: NCT00321087

Locations: 🇨🇦
Investigator Site, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy